nanatinostat + valganciclovir + pembrolizumab

A **triple combination therapy** designed for the treatment of cancers, particularly Epstein-Barr virus (EBV)-positive lymphomas and related malignancies. - **Nanatinostat** is a class I selective histone deacetylase (HDAC) inhibitor that modulates gene expression, including reactivation and immune visibility of latent viral genomes (e.g., EBV). - **Valganciclovir** is an oral prodrug of ganciclovir, a nucleoside analogue with antiviral activity against herpesviruses, used to enhance the cytolytic effect when viruses are reactivated. - **Pembrolizumab** is a monoclonal antibody that targets PD-1 (programmed death receptor-1), blocking its interaction with PD-L1/PD-L2 to boost anti-tumor immune responses. This combination aims to: - **Reactivate EBV in tumor cells (via nanatinostat)**, - **Kill the reactivated cells with antiviral therapy (valganciclovir)**, and - **Enhance host anti-tumor immunity (pembrolizumab)**. Primary indication is investigational for **EBV-positive lymphoma**, but also being developed for other cancers where EBV is implicated. Developers and manufacturers are tied to each constituent: nanatinostat (Viracta Therapeutics), valganciclovir (originally Roche), pembrolizumab (Merck).